CBS News, November 30, 2016. Dr. Diana Zuckerman of the National Center For Health Research described the Cures Act as a “misnomer to start with.” She cited two issues with the bill: it lowers the standards for medical products, drugs and devices — and the money outlined in the bill is promised, not guaranteed.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Congress Poised To Pass Sweeping Law Covering FDA And NIH
NPR and WBUR, November 29, 2016. NCHR President, Diana Zuckerman, says she’s concerned that the 21st Century Cures act will make it even easier for drug companies to use the express lane for approval.
Read More »Lawmakers Try for Year-End Bill on Medical Research, Devices and Opioid Addiction
Wall Street Journal, November 30, 2016. Negotiators still need to hammer out agreement in some areas, including GOP proposals for limiting FDA regulation.
Read More »Patients Increasingly Influence the Direction of Medical Research
NPR, November 28, 2016. “The bad news is that so much of patient input is involving patients who are working with or who are recruited by drug companies,” cautions NCHR’s Diana Zuckerman.
Read More »A Frenzy of Lobbying on 21st Century Cures
Kaiser Health News, November 28, 2016. Beyond the pharmaceutical industry, the bill’s supporters include universities, medical schools and groups representing them, as well as patient groups funded by drug and device companies. “It really is a David and Goliath issue of where the money is,” NCHR president Diana Zuckerman said.
Read More »